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COVID-19—a very visible 
pandemic
We read the Correspondence by 
Johan Giesecke,1 a senior consultant 
to the Swedish Public Health Agency, 
with considerable concern.
First, Giesecke correctly placed the 
Swedish death toll at less than the 
UK, Spain, and Belgium, and at more 
than its Nordic neighbours. But he did 
not acknowledge the scale of these 
differences. Despite similar epidemic 
start dates, population densities, 
and cultures, at the time of writing, 
Sweden had reported 7 times more 
COVID-19 deaths per person than 
Finland and Norway, and 3 times more 
than Denmark.
Secondly, to state that 98–99% 
of people infected with COVID-19 
are “unaware or uncertain of having 
had the infection”1 dangerously 
conflates asymptomatic cases with 
unconfirmed cases, and dismisses the 
lived experience of milder infections. 
Although a summary of 13 studies 
estimates that 56% of cases are 
asymptomatic at the point of testing, 
many go on to develop symptoms.2 For 
Giesecke1 to state that “COVID-19 is 
spreading like wildfire in all countries, 
but we do not see it” is contradictory.
Giesecke’s further assertion that, 
as of April 29, 2020, 20–25% of the 
Stockholm region have been infected 
only serves to reinforce his opinion of 
unreported cases. But this assertion 
is based on a narrow view of available 
data at that time. Of the three prelim-
inary and unpublished serology studies 
from Stockholm in April, 2020, only 
one study, testing 527 of 2000 health-
care workers at a single hospital, is close 
to this estimate (20% seropositive).3 
However, community estimates range 
from 7·5% to 10%, and suggest consid-
erable clustering.4,5
Indeed, serology data from other 
European settings in March and April, 
2020, report low antibody prevalence, 
from less than 1·0% to 2·7% among 
tested blood donors;6,7 5·5% from a 
random population sample in Geneva;8 
and 11·2% from health-care workers 
in Spain.9 The hotspot of Gangelt in 
Germany reported 15% patients with 
an infection,10 substantially lower than 
the assumed 50–70% threshold needed 
for herd immunity. Therefore, it seems 
implausible to suggest that Europe 
is past the peak because of so-called 
silently acquired herd immunity, rather 
than as a result of active intervention.
Finally, the conclusion that stopping 
the spread of COVID-19 is futile ignores 
clear examples from New Zealand, 
Taiwan, Iceland, and Vietnam. It 
is disingenuous to dismiss these 
considerable successes of COVID-19 
containment and, at least temporarily, 
suppression. The threat of future 
outbreaks is of course a real concern—
look to Singapore for a stark warning.
But to state that slowing down the 
progression of COVID-19 is futile is 
cynical, as it implies that painfully 
acquired knowledge and efforts 
to develop or repurpose drugs and 
treatments will amount to nothing.
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